

Ai-Ming Yu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7870801/ai-ming-yu-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

4,798
citations

39
h-index

64
g-index

142
ext. papers

5,537
ext. citations

5.9
avg, IF

6
L-index

#	Paper	IF	Citations
127	Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.. <i>Medical Oncology</i> , 2022 , 39, 87	3.7	
126	Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.. <i>Bioengineered</i> , 2022 , 13, 12489-12503	5.7	1
125	Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models. <i>Methods in Molecular Biology</i> , 2022 , 191-206	1.4	
124	Targeting Feedforward Loops Formed by Nuclear Receptor ROR α and Kinase PBK in mCRPC with Hyperactive AR Signaling. <i>Cancers</i> , 2021 , 13,	6.6	3
123	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. <i>Oncogene</i> , 2021 , 40, 5379-5392	9.2	5
122	Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth. <i>Biochemical Pharmacology</i> , 2021 , 189, 114392	6	3
121	fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. <i>Theranostics</i> , 2021 , 11, 4858-4871	12.1	6
120	A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine Synergism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 377, 305-315	4.7	1
119	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. <i>Pharmacology & Therapeutics</i> , 2021 , 230, 107967	13.9	7
118	Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis .. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 3950-3965	15.5	3
117	Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs. <i>Methods in Molecular Biology</i> , 2021 , 2323, 249-265	1.4	2
116	The Optimal Outcome of Suppressing Ewing Sarcoma Growth With Biocompatible Bioengineered miR-34a-5p Prodrug. <i>Frontiers in Oncology</i> , 2020 , 10, 222	5.3	3
115	A novel miR-1291-ERRECEPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis. <i>Theranostics</i> , 2020 , 10, 7193-7210	12.1	17
114	Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1070-1079	6.1	10
113	Novel approaches for efficient in vivo fermentation production of noncoding RNAs. <i>Applied Microbiology and Biotechnology</i> , 2020 , 104, 1927-1937	5.7	15
112	Carnitine palmitoyltransferase 1C contributes to progressive cellular senescence. <i>Aging</i> , 2020 , 12, 6733-6755	6.55	2
111	Bioengineered miR-328-3p modulates SLC2A1/GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	

110	Bioengineered microRNAs suppress lung cancer cell metabolism and proliferation through targeting of folate cycle. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
109	A novel integrated PK/PD model to assess combination therapy: Determination of the synergistic antitumor efficacy between doxorubicin and sorafenib. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
108	A reliable LC-MS/MS method for targeted analysis of amino acid metabolome: Method validation and application to studies on amino acid dynamics during tumor progression. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
107	A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2020 , 80, 418-429	10.1	26
106	Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. <i>Acta Pharmaceutica Sinica B</i> , 2020 , 10, 159-170	15.5	33
105	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 1257-1263	4	6
104	MicroRNA-1291-5p Sensitizes Pancreatic Carcinoma Cells to Arginine Deprivation and Chemotherapy through the Regulation of Arginolysis and Glycolysis. <i>Molecular Pharmacology</i> , 2020 , 98, 686-694	4.3	10
103	RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. <i>Pharmacological Reviews</i> , 2020 , 72, 862-898	22.5	69
102	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	16
101	Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. <i>Biochemical Pharmacology</i> , 2019 , 169, 113638	6	21
100	A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1124, 72-81	3.2	16
99	Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs. <i>Applied Microbiology and Biotechnology</i> , 2019 , 103, 6107-6117	5.7	17
98	Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. <i>Biomaterials</i> , 2019 , 210, 25-40	15.6	24
97	Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. <i>Translational Oncology</i> , 2019 , 12, 683-692	4.9	8
96	Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition the regulation of target ADME gene expression. <i>Acta Pharmaceutica Sinica B</i> , 2019 , 9, 639-647	15.5	34
95	Effects of carnitine palmitoyltransferases on cancer cellular senescence. <i>Journal of Cellular Physiology</i> , 2019 , 234, 1707-1719	7	17
94	Current trends in drug metabolism and pharmacokinetics. <i>Acta Pharmaceutica Sinica B</i> , 2019 , 9, 1113-1144	14.5	65
93	Bioengineering of single ncRNA molecule for multi-targeting against NSCLC. <i>FASEB Journal</i> , 2019 , 33, 674.12	0.9	

92	Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 14, 498-508	10.7	22
91	MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00528	3.1	39
90	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. <i>Cancer Letters</i> , 2019 , 442, 82-90	9.9	32
89	RNA therapy: Are we using the right molecules?. <i>Pharmacology & Therapeutics</i> , 2019 , 196, 91-104	13.9	76
88	Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 365, 494-506	4.7	33
87	Carnitine palmitoyltransferase 1C regulates cancer cell senescence through mitochondria-associated metabolic reprogramming. <i>Cell Death and Differentiation</i> , 2018 , 25, 735-748	12.7	35
86	Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 2-10	4	43
85	Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo. <i>International Journal of Pharmaceutics</i> , 2018 , 547, 537-544	6.5	24
84	MicroRNA-1291 effects on pancreatic cancer (PC) cells sensitivity to arginine deprivation and chemotherapy through modulation of ASS1 and GLUT1.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 334-334	2.2	2
83	Bioengineering of single ncRNA molecule for multi-targeting against NSCLC. <i>FASEB Journal</i> , 2018 , 32, 565.1	0.9	
82	Bioengineered let-7c is Effective at Reducing Orthotopic Hepatocellular Carcinoma Tumor Burden and is Well Tolerated in Mouse Models. <i>FASEB Journal</i> , 2018 , 32, 565.2	0.9	
81	A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma. <i>PLoS ONE</i> , 2018 , 13, e0209941	3.7	9
80	Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury. <i>Biopharmaceutics and Drug Disposition</i> , 2017 , 38, 326-339	1.7	8
79	Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling. <i>Placenta</i> , 2017 , 51, 57-63	3.4	21
78	Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 512-522	4	18
77	PPAR γ regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C. <i>Carcinogenesis</i> , 2017 , 38, 474-483	4.6	33
76	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21 International Symposium on Microsomes and Drug Oxidations (MDO). <i>Acta Pharmaceutica Sinica B</i> , 2017 , 7, 241-248	15.5	17
75	Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. <i>Oncotarget</i> , 2017 , 8, 30742-30755	3.3	20

74	Bioengineered non-coding RNA agent (BERA) in action. <i>Bioengineered</i> , 2016 , 7, 411-417	5.7	19
73	Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. <i>Scientific Reports</i> , 2016 , 6, 26611	4.9	34
72	Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. <i>Pharmacological Reports</i> , 2016 , 68, 608-15	3.9	8
71	MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 308-19	4	46
70	Lyme disease spirochaete <i>Borrelia burgdorferi</i> does not require thiamin. <i>Nature Microbiology</i> , 2016 , 2, 16213	26.6	16
69	Impact and mechanistic role of MicroRNA-1291 on pancreatic tumorigenesis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 243-243	2.2	1
68	MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. <i>Oncotarget</i> , 2016 , 7, 45547-45561	3.3	30
67	Bioengineering of noncoding RNAs for research agents and therapeutics. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016 , 7, 186-97	9.3	44
66	Metabolomics reveals mycoplasma contamination interferes with the metabolism of PANC-1 cells. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 4267-73	4.4	10
65	Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 93, 431-6	5.1	8
64	Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. <i>Acta Pharmaceutica Sinica B</i> , 2016 , 6, 492-503	15.5	3
63	Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 354, 131-41	4.7	42
62	A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. <i>Nucleic Acids Research</i> , 2015 , 43, 3857-69	20.1	51
61	Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. <i>Biochemical Pharmacology</i> , 2015 , 98, 602-13	6	49
60	Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress. <i>Cellular Physiology and Biochemistry</i> , 2015 , 35, 710-21	3.9	40
59	Chimeric MicroRNA-1291 Biosynthesized Efficiently in <i>Escherichia coli</i> Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1129-36	4	37
58	Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. <i>Neuropharmacology</i> , 2015 , 89, 342-51	5.5	11
57	Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes. <i>Current Drug Metabolism</i> , 2015 , 16, 877-93	3.5	9

56	Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. <i>Journal of Biological Chemistry</i> , 2014 , 289, 3105-13	5.4	38
55	Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1791-5	4	27
54	Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression. <i>Acta Pharmaceutica Sinica B</i> , 2014 , 4, 350-7	15.5	1
53	N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. <i>Carcinogenesis</i> , 2014 , 35, 2264-72	4.6	34
52	ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. <i>Current Pharmaceutical Design</i> , 2014 , 20, 793-807	3.3	304
51	Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1725-31	4	57
50	Potential role of CYP2D6 in the central nervous system. <i>Xenobiotica</i> , 2013 , 43, 973-84	2	46
49	Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 975-86	4	20
48	Study of the response regulator Rrp1 reveals its regulatory role in chitobiose utilization and virulence of <i>Borrelia burgdorferi</i> . <i>Infection and Immunity</i> , 2013 , 81, 1775-87	3.7	51
47	Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1744-51	4	62
46	An overview of ABC and SLC Drug Transporter Gene Regulation. <i>Current Drug Metabolism</i> , 2013 , 14, 253-264	3.5	10
45	Noncoding microRNAs: small RNAs play a big role in regulation of ADME?. <i>Acta Pharmaceutica Sinica B</i> , 2012 , 2, 93-101	15.5	35
44	miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3'UTRs of human genes. <i>BMC Genomics</i> , 2012 , 13, 44	4.5	129
43	Genetically Modified Mouse Models in ADME Studies 2012 , 235-454		1
42	Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. <i>Current Drug Metabolism</i> , 2011 , 12, 997-1006	3.5	23
41	Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice. <i>Pharmacology Biochemistry and Behavior</i> , 2011 , 99, 311-5	3.9	9
40	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. <i>Biochemical Pharmacology</i> , 2011 , 81, 783-92	6	92
39	MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. <i>Biopharmaceutics and Drug Disposition</i> , 2011 , 32, 355-67	1.7	39

38	Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. <i>Drug Metabolism Reviews</i> , 2011 , 43, 27-40	7	30
37	Altered cytochrome P450 expression in mice during pregnancy. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 165-9	4	36
36	The riboswitch regulates a thiamine pyrophosphate ABC transporter of the oral spirochete <i>Treponema denticola</i> . <i>Journal of Bacteriology</i> , 2011 , 193, 3912-22	3.5	22
35	Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1227-34	4	20
34	Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. <i>Current Drug Metabolism</i> , 2010 , 11, 659-66	3.5	89
33	Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. <i>Biochemical Pharmacology</i> , 2010 , 80, 122-8	6	27
32	Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 170-7	4	20
31	Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study. <i>Bioanalysis</i> , 2009 , 1, 87-95	2.1	19
30	Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1-4	4	27
29	Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. <i>Biochemical Pharmacology</i> , 2009 , 78, 617-24	6	39
28	MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. <i>Molecular Pharmacology</i> , 2009 , 75, 1374-9	4.3	249
27	Pinoline may be used as a probe for CYP2D6 activity. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 443-6	4	29
26	Role of microRNAs in the regulation of drug metabolism and disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 1513-28	5.5	47
25	MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 2112-7	4	201
24	Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. <i>Drug Metabolism Letters</i> , 2009 , 3, 234-41	2.1	6
23	Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 435-41	4	49
22	Indolealkylamines: biotransformations and potential drug-drug interactions. <i>AAPS Journal</i> , 2008 , 10, 242-53	3.7	41
21	Small interfering RNA in drug metabolism and transport. <i>Current Drug Metabolism</i> , 2007 , 8, 700-8	3.5	33

20	Expression, purification, and characterization of mouse CYP2d22. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1167-74	4	23
19	Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. <i>Journal of Lipid Research</i> , 2006 , 47, 215-27	6.3	102
18	Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 1328-34	4.7	76
17	Cytochrome P450 and xenobiotic receptor humanized mice. <i>Annual Review of Pharmacology and Toxicology</i> , 2006 , 46, 41-64	17.9	129
16	Potential role for human cytochrome P450 3A4 in estradiol homeostasis. <i>Endocrinology</i> , 2005 , 146, 2911-18	4.8	66
15	The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 449-57	4	136
14	Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 2480-9	5.4	73
13	Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. <i>Drug Metabolism Reviews</i> , 2004 , 36, 243-77	7	102
12	Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 548-58	4	93
11	The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 304, 539-46	4.7	47
10	. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 307-319		113
9	. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 173-181		155
8	Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 315-22	4.7	109
7	Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. <i>Carcinogenesis</i> , 2003 , 24, 583-7	4.6	35
6	Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 307-19		45
5	Cytochrome P450 Pharmacogenetics 2003 , 375-419		1
4	Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 173-81		53
3	Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , 2002 , 63, 2111-9	6	52

2	Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 1291-300	4.7	83
1	Purification, biochemical characterization and comparative enzyme kinetics of recombinant human CYP2D6 1 and CYP2D6 2 variants. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 500, 327-30	3.6	1